Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin
Open Access
- 1 October 1989
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 33 (10) , 1783-1790
- https://doi.org/10.1128/aac.33.10.1783
Abstract
Twelve volunteers, in two groups of six, received daptomycin at a dose of 1 or 2 mg/kg. In addition, they received in a randomly allocated order amikacin (500 mg), daptomycin-amikacin, and vancomycin (500 mg). Thirty-five clinical isolates, including Staphylococcus aureus, S. epidermidis, Corynebacterium sp. group JK, and Enterococcus faecalis, were tested in vitro for the measure of the serum bactericidal titers and killing rates. The mean peak concentrations of daptomycin in serum 1 h after the administration of 1 and 2 mg/kg were 11 and 20 micrograms/ml, respectively. At 24 h after the administration of 2 mg/kg, the mean level in serum was 1.9 micrograms/ml, which is higher than the MICs for susceptible pathogens. Daptomycin and amikacin provided identical concentrations in serum whether given alone or in combination. Among the six regimens tested, those including daptomycin provided the highest and the most prolonged serum bactericidal titers against S. aureus, S. epidermidis, and E. faecalis. The killing rates measured by the killing curves were correlated with the concentration/MIC and concentration/MBC ratios of daptomycin for all strains tested. Significant killing occurred once the concentration of daptomycin in the serum 4- to 6-fold the MIC or 1- to 1.2-fold the MBC. The combination of daptomycin and amikacin had no effect on either the serum bactericidal titers or the rates of killing. Only vancomycin provided significant killing of the strains of Corynebacterium sp. group JK.Keywords
This publication has 28 references indexed in Scilit:
- Pharmacokinetics of teicoplanin in pediatric patientsAntimicrobial Agents and Chemotherapy, 1988
- In-vitro activity of LY146032 against Staphylococcus aureus, Listeria monocytogenes, Corynebacterium JK, and Bacillus spp., in comparison with various antibioticsJournal of Antimicrobial Chemotherapy, 1987
- Emergence of Vancomycin Resistance in Coagulase-Negative StaphylococciNew England Journal of Medicine, 1987
- Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory ConcentrationThe Journal of Infectious Diseases, 1987
- Correlation of predicted serum bactericidal activities and values measured in volunteersEuropean Journal of Clinical Microbiology & Infectious Diseases, 1986
- Serum Bactericidal Activity as a Monitor of Antibiotic TherapyNew England Journal of Medicine, 1985
- Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapyEuropean Journal of Cancer and Clinical Oncology, 1984
- Vancomycin pharmacokinetics in normal and morbidly obese subjectsAntimicrobial Agents and Chemotherapy, 1982
- Single‐Dose Kinetics of Intravenous VancomycinThe Journal of Clinical Pharmacology, 1980
- Serum Dilution Test for Bactericidal Activity. II. Standardization and Correlation with Antimicrobial Assays and Susceptibility TestsThe Journal of Infectious Diseases, 1977